Advertisement
Screener

TuHURA BIOSCIENCES, INC./NV (HURA) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

1.9 / 5 stars · 15/40 Roast Me

TuHURA BIOSCIENCES, INC./NV Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

TuHURA BIOSCIENCES, INC./NV (HURA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$16.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-14

  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$9.22M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$7.54M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$6.76M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$7.10M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$30.05M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$21.68M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$8.32M.
  • TuHURA BIOSCIENCES, INC./NV net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$29.32M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 36 month
2026-06-30-$9.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$16.76M
10-Q · filed 2026-08-14
-$23.52M
derived: sum of 3 quarters · filed 2026-08-14
-$30.62M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$7.54M
10-Q · filed 2026-05-15
-$14.30M
derived: sum of 2 quarters · filed 2026-05-15
-$21.40M
derived: sum of 3 quarters · filed 2026-05-15
-$30.92M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$6.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$13.86M
derived: sum of 2 quarters · filed 2026-03-31
-$23.39M
derived: sum of 3 quarters · filed 2026-08-14
-$30.05M
10-K · filed 2026-03-31
2025-09-30-$7.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-$16.63M
derived: sum of 2 quarters · filed 2026-08-14
-$23.29M
10-Q · filed 2025-11-14
-$29.29M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$9.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$16.19M
10-Q · filed 2026-08-14
-$22.18M
derived: sum of 3 quarters · filed 2026-08-14
-$24.35M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$6.66M
10-Q · filed 2026-05-15
-$12.66M
derived: sum of 2 quarters · filed 2026-05-15
-$14.82M
derived: sum of 3 quarters · filed 2026-05-15
-$20.09M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$6.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$8.16M
derived: sum of 2 quarters · filed 2026-03-31
-$13.42M
derived: sum of 3 quarters · filed 2026-03-31
-$21.68M
10-K · filed 2026-03-31
2024-09-30-$2.16M
10-Q · filed 2024-11-14
-$7.43M
derived: sum of 2 quarters · filed 2025-08-14
-$15.69M
10-Q · filed 2025-11-14
-$13.29M
derived: sum of 4 quarters · filed 2025-08-14
2024-06-30-$5.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$10.11M
10-Q · filed 2025-08-14
-$11.13M
derived: sum of 3 quarters · filed 2025-08-14
-$8.32M
10-K · filed 2024-10-07
2024-03-31-$4.84M
10-Q · filed 2025-05-15
-$2.01M
10-Q · filed 2024-05-14
-$5.87M
derived: sum of 2 quarters · filed 2025-05-15
-$6.00M
10-Q · filed 2024-05-14
-$12.16M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$1.02M
10-Q · filed 2024-05-14
-$3.98M
10-Q · filed 2024-02-14
-$7.32M
derived: sum of 3 quarters · filed 2024-11-14
-$29.32M
10-K · filed 2025-03-31
2023-09-30-$2.96M
10-Q · filed 2024-11-14
-$6.30M
derived: sum of 2 quarters · filed 2024-11-14
-$9.56M
derived: sum of 3 quarters · filed 2024-11-14
-$13.02M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$3.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-07
-$6.60M
derived: sum of 2 quarters · filed 2024-10-07
-$10.05M
derived: sum of 3 quarters · filed 2024-10-07
-$14.65M
10-K · filed 2024-10-07
2023-03-31-$3.26M
10-Q · filed 2024-05-14
-$6.72M
derived: sum of 2 quarters · filed 2024-05-14
-$11.31M
10-Q · filed 2024-05-14
-$16.76M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$3.45M
10-Q · filed 2024-05-14
-$8.05M
10-Q · filed 2024-02-14
-$13.50M
derived: sum of 3 quarters · filed 2024-05-14
-$18.85M
derived: sum of 4 quarters · filed 2024-05-14
2022-09-30-$4.60M
10-Q · filed 2024-05-14
-$10.04M
derived: sum of 2 quarters · filed 2024-05-14
-$15.40M
derived: sum of 3 quarters · filed 2024-05-14
-$21.29M
derived: sum of 4 quarters · filed 2024-05-14
2022-06-30-$5.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-18
-$10.80M
derived: sum of 2 quarters · filed 2023-09-18
-$16.70M
derived: sum of 3 quarters · filed 2023-09-18
-$22.66M
10-K · filed 2023-09-18
2022-03-31-$5.36M
10-Q · filed 2023-05-11
-$11.25M
derived: sum of 2 quarters · filed 2023-05-11
-$17.21M
10-Q · filed 2023-05-11
-$23.95M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$5.89M
10-Q · filed 2023-05-11
-$11.86M
10-Q · filed 2023-02-14
-$18.59M
derived: sum of 3 quarters · filed 2023-05-11
-$25.23M
derived: sum of 4 quarters · filed 2023-05-11
2021-09-30-$5.97M
10-Q · filed 2023-05-11
-$12.70M
derived: sum of 2 quarters · filed 2023-05-11
-$19.33M
derived: sum of 3 quarters · filed 2023-05-11
-$24.75M
derived: sum of 4 quarters · filed 2023-05-11
2021-06-30-$6.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27
-$13.37M
derived: sum of 2 quarters · filed 2022-09-27
-$18.78M
derived: sum of 3 quarters · filed 2022-09-27
-$38.30M
10-K · filed 2022-09-27
2021-03-31-$6.63M
10-Q · filed 2022-05-13
-$12.05M
derived: sum of 2 quarters · filed 2022-05-13
-$31.57M
10-Q · filed 2022-05-13
-$35.39M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$5.41M
10-Q · filed 2022-05-13
-$24.93M
10-Q · filed 2022-02-11
-$28.75M
derived: sum of 3 quarters · filed 2022-05-13
-$30.71M
derived: sum of 4 quarters · filed 2022-05-13
2020-09-30-$19.52M
10-Q · filed 2022-05-13
-$23.34M
derived: sum of 2 quarters · filed 2022-05-13
-$25.30M
derived: sum of 3 quarters · filed 2022-05-13
-$27.04M
derived: sum of 4 quarters · filed 2022-05-13
2020-06-30-$3.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28
-$5.78M
derived: sum of 2 quarters · filed 2021-09-28
-$7.52M
derived: sum of 3 quarters · filed 2021-09-28
-$9.13M
10-K · filed 2021-09-28
-$9.13M
10-K · filed 2020-09-18
2020-03-31-$1.96M
10-Q · filed 2021-05-13
-$1.96M
10-Q · filed 2020-05-13
-$3.70M
derived: sum of 2 quarters · filed 2021-05-13
-$5.30M
10-Q · filed 2021-05-13
-$7.89M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$1.74M
10-Q · filed 2021-05-13
-$1.74M
10-Q · filed 2020-02-13
-$3.35M
10-Q · filed 2021-02-12
-$5.93M
derived: sum of 3 quarters · filed 2021-05-13
-$7.59M
derived: sum of 4 quarters · filed 2021-05-13
2019-09-30-$1.61M
10-Q · filed 2021-05-13
-$1.61M
10-Q · filed 2019-11-13
-$4.19M
derived: sum of 2 quarters · filed 2021-05-13
-$5.85M
derived: sum of 3 quarters · filed 2021-05-13
-$7.66M
derived: sum of 4 quarters · filed 2021-05-13
2019-06-30-$2.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-18
-$4.25M
derived: sum of 2 quarters · filed 2020-09-18
-$6.06M
derived: sum of 3 quarters · filed 2020-09-18
-$8.05M
10-K · filed 2020-09-18
2019-03-31-$1.66M
10-Q · filed 2020-05-13
-$3.47M
derived: sum of 2 quarters · filed 2020-05-13
-$5.47M
10-Q · filed 2019-05-14
-$7.84M
derived: sum of 4 quarters · filed 2020-05-13
2018-12-31-$1.81M
10-Q · filed 2020-05-13
-$3.80M
10-Q · filed 2019-02-11
-$6.18M
derived: sum of 3 quarters · filed 2020-05-13
-$9.11M
derived: sum of 4 quarters · filed 2020-05-13
2018-09-30-$1.99M
10-Q · filed 2020-05-13
-$4.37M
derived: sum of 2 quarters · filed 2020-05-13
-$7.30M
derived: sum of 3 quarters · filed 2020-05-13
-$10.46M
derived: sum of 4 quarters · filed 2020-05-13
2018-06-30-$2.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-09
-$5.31M
derived: sum of 2 quarters · filed 2019-09-09
-$8.47M
derived: sum of 3 quarters · filed 2019-09-09
-$11.14M
10-K · filed 2019-09-09
2018-03-31-$2.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14
-$6.09M
derived: sum of 2 quarters · filed 2019-05-14
-$8.76M
10-Q · filed 2019-05-14
2017-12-31-$3.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-11
-$5.83M
10-Q · filed 2019-02-11
2017-09-30-$2.67M
10-Q · filed 2018-11-13
2017-06-30-$8.08M
8-K · filed 2019-06-03
2012-06-30-$982.00
10-K/A · filed 2012-12-20
-$18.89K
10-K/A · filed 2012-12-20
-$57.69K
10-K/A · filed 2012-12-20
2011-06-30-$6.83K
10-K/A · filed 2012-12-20
-$33.21K
10-K/A · filed 2012-12-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72